Advinus Therapeutics is planning an expansion programme with an investment of Rs. 3000 million. The company promoted with
funding from Tata Group to the tune of Rs.2000 million in 2005 had recently discovered a new drug moleculed "GKM-001" for type
II diabetics. It is expanding its human resources and plans to double its development programmes from current 6-7 to 13-14
programmes. It will also look at drugs for aged like Parkinson's, Alzheimer's, frailty, arthritis and brittle bones. Advinus would double
the Pune team to 500 and add 50 more to the Bangalore team of 350, taking the total to 900. The company, which runs on the
model of contract research for global partners at Bangalore and drug discovery done at Pune, expects to touch a turnover of Rs
100 crore this fiscal
